Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives

SYDNEY, Australia, April 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Intellectual Property Department of the Hong Kong Special Administrative Region has granted patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection,” furthering marketing and manufacturing exclusivity to February 2037.

“As we continue to build our patent portfolio in key geographies and major medical markets, this newly granted patent is another endorsement for our commercial and clinical development strategy highlighting the potential of our Australian anti-infective technology,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

The Intellectual Property Department of the Hong Kong Special Administrative Region has granted claims relating to RECCE® 327 (R327) and anti-viral formulation RECCE® 529 (R529), most notably:

  • Composition/method of manufacture of RECCE® anti-infectives
  • Use of R327 or R529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and coronaviruses, influenza viruses, human immunodeficiency virus (HIV), hepatitis, ross river and herpesviruses
  • Administration of R327 or R529 by oral, injection, inhalation and transdermal dose applications

The pharmaceutical market in Hong Kong is valued at USD $2.3 billion, with rising demand for chronic disease treatment.1

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.

Corporate Contact
James Graham
Recce Pharmaceuticals Ltd
+61 (02) 9256 2571

Media and Investor Relations (AU)
Andrew Geddes
+61 (02) 9267 4511

Media and Investor Relations (USA)
Jordyn Temperato
LifeSci Communications



Primary Logo

Back to news